{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:31:58Z","timestamp":1786606318046,"version":"build-2736575974"},"reference-count":72,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This article reviews the published data encompassing the development, pharmacology, efficacy, and safety of obecabtagene autoleucel, summarizing data from pivotal clinical studies and clinical relevance in the treatment of relapsed or refractory (R\/R) B-cell precursor acute lymphoblastic leukemia (B-ALL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature review was conducted in PubMed and Clinicaltrials.gov from inception through May 2026, using terms \u201cAUCATZYL\u00ae,\u201d \u201cobecabtagene autoleucel,\u201d \u201cobe-cel,\u201d \u201cAUTO1,\u201d and \u201cCAR-T cell therapy.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Clinical data and studies were limited to those published in the English language which discussed the safety and efficacy of obecabtagene autoleucel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Obecabtagene autoleucel (obe-cel) is an autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy using a novel CAT19 single-chain variable fragment designed with an intermediate affinity and fast binding off-rate mechanism. In the pivotal FELIX study, an overall remission rate of 77% was achieved in the primary adult cohort (IIa), with a median event-free survival rate of 11.9\u2009months across all cohorts. Safety data indicate a manageable toxicity profile, and economic models suggest significant cost savings regarding adverse event management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents:<\/jats:title>\n                    <jats:p>Obe-cel provides a new treatment option for adults with R\/R B-ALL, a population that historically faces poor prognosis and high recurrence rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>While logistical complexities and high acquisition costs remain an access barrier to CAR-T cell therapies, obe-cel\u2019s molecular design and safety profile represent a significant advancement in the care of patients with R\/R B-ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261470829","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:13:49Z","timestamp":1786349629000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Obecabtagene Autoleucel in Relapsed\/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety"],"prefix":"10.1177","author":[{"given":"Emily","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timber","family":"Abinsay","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Angelo","family":"Confiado","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Cobb","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4738-7392","authenticated-orcid":false,"given":"Kelli","family":"Corona","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4606-2511","authenticated-orcid":false,"given":"Lauren","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-2108","authenticated-orcid":false,"given":"Jessica","family":"Huston","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Chennamadhavuni A Iyengar V Mukkamalla SKR Shimanovsky A. Leukemia. [Updated January 17 2023]. StatPearls; 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560490\/"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000711"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27708"},{"key":"e_1_3_2_6_2","unstructured":"PDQ\u00ae Pediatric Treatment Editorial Board. PDQ childhood acute lymphoblastic leukemia treatment. National Cancer Institute Updated April 21 2025. Accessed January 3 2026. https:\/\/www.cancer.gov\/types\/leukemia\/hp\/child-alltreatment-pdq"},{"key":"e_1_3_2_7_2","unstructured":"American Cancer Society. Key statistics for acute lymphocytic leukemia (ALL). Accessed January 15 2026. https:\/\/www.cancer.org\/cancer\/types\/acute-lymphocyticleukemia\/about\/key-statistics.html"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2014.073"},{"key":"e_1_3_2_10_2","unstructured":"National Comprehensive Cancer Network. Acute lymphoblastic leukemia (Version 1.2026). Accessed June 10 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf"},{"key":"e_1_3_2_11_2","unstructured":"National Cancer Institute. [Complete Remission]. NCI dictionary of cancer terms. Accessed May 20 2026. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/complete-remission"},{"key":"e_1_3_2_12_2","unstructured":"National Cancer Institute. [Relapse]. NCI dictionary of cancer terms. Accessed May 20 2026. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/search\/relapse\/?searchMode=Begins."},{"key":"e_1_3_2_13_2","unstructured":"National Cancer Institute. [Refractory]. NCI dictionary of cancer terms. Accessed May 20 2026. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/search\/refractory\/?searchMode=Begins."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009462"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489827"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144787"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1535370215584936"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010586"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay8248"},{"issue":"5","key":"e_1_3_2_22_2","first-page":"537","article-title":"Tisagenlecleucel: The first CAR on the highway to remission for acute lymphoblastic leukemia","volume":"9","author":"Freyer CW.","year":"2018","unstructured":"Freyer CW. Tisagenlecleucel: The first CAR on the highway to remission for acute lymphoblastic leukemia. J Adv Pract Oncol. 2018;9(5):537-544.","journal-title":"J Adv Pract Oncol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433075"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"e_1_3_2_27_2","unstructured":"National Comprehensive Cancer Network. Management of CAR-T cell and lymphocyte engager-related toxicities (Version 2.2026). Accessed June 10 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.46989\/001c.124277"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020621"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00917"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa24065267"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001249"},{"key":"e_1_3_2_33_2","article-title":"AUCATZYL\u00ae (obecabtagene autoleucel)","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. AUCATZYL\u00ae (obecabtagene autoleucel) [package insert]. Autolus Limited; 2024.","journal-title":"Autolus Limited;"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288587"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00476-2"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16623"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"McKiever M Pereiras M Lee G Donato ML. Lymphodepletion with Fludarabine\/Cyclophosphamide shows higher complete response rates compared to bendamustine prior to CAR-T therapy. Blood. 2024;144(Suppl. 1): 3460. doi:https:\/\/doi.org\/10.1182\/blood-2024-211140","DOI":"10.1182\/blood-2024-211140"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1798"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5412"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-025-00586-x"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.06.001"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025828"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2401361"},{"key":"e_1_3_2_46_2","unstructured":"CARPALL: Immunotherapy with CD19+CD22 CAR redirected T-cells for high risk\/relapsed paediatric CD19+ and CD22+ acute lymphoblastic leukaemia (CARPALL). ClinicalTrials.gov Identifier: NCT02443831. https:\/\/clinicaltrials.gov\/study\/NCT02443831"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5"},{"key":"e_1_3_2_48_2","unstructured":"Immunotherapy for high risk\/relapsed CD19+ acute lymphoblastic leukaemia B-cell non-Hodgkin\u2019s lymphoma (B-NHL) and chronic lymphocytic leukaemia (CLL)\/small lymphocytic lymphoma (SLL) using CAR T-cells to target CD19 (ALLCAR19). ClinicalTrials.gov Identifier: NCT02935257. https:\/\/clinicaltrials.gov\/study\/NCT02935257"},{"key":"e_1_3_2_49_2","unstructured":"A study of CD19 targeted CAR T cell therapy in adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia (ALL). ClinicalTrials.gov Identifier: NCT04404660. https:\/\/clinicaltrials.gov\/study\/NCT04404660"},{"key":"e_1_3_2_50_2","unstructured":"Phase 2 study assessing the clinical activity and safety of obecabtagene autoleucel as a consolidation in patients with newly diagnosed high-risk b-cell acute lymphocytic leukemia (ALL). ClinicalTrials.gov Identifier: NCT07053059. https:\/\/clinicaltrials.gov\/study\/NCT07053059?intr=NCT07053059&viewType=Card&rank=1"},{"key":"e_1_3_2_51_2","unstructured":"A phase II trial of obecabtagene autoleucel consolidation in adult patients with acute lymphoblastic leukemia in first complete remission without measurable residual disease. ClinicalTrials.gov Identifier: NCT07400029. https:\/\/clinicaltrials.gov\/study\/NCT07400029?term=NCT07400029&viewType=Card&rank=1"},{"key":"e_1_3_2_52_2","unstructured":"A single-arm open-label multicenter phase 1b\/2 study evaluating the safety and efficacy of AUTO1 (Obecabtagene Autoleucel [Obe-cel]) in pediatric patients with CD19-positive relapsed\/refractory (R\/R) B cell acute lymphoblastic leukemia (B ALL) or R\/R aggressive mature B Cell Non-Hodgkin Lymphoma (B NHL). ClinicalTrials.gov Identifier: NCT06173518. https:\/\/clinicaltrials.gov\/study\/NCT06173518?intr=NCT06173518&viewType=Card&rank=1"},{"key":"e_1_3_2_53_2","unstructured":"A single-arm open-label phase II study to determine the safety and efficacy of obecabtagene autoleucel (Obe-cel) in participants with severe refractory systemic lupus erythematosus with active lupus nephritis. ClinicalTrials.gov Identifier: NCT07053800. https:\/\/clinicaltrials.gov\/study\/NCT07053800?intr=NCT07053800&viewType=Card&rank=1"},{"key":"e_1_3_2_54_2","unstructured":"A single-arm open-label phase I study to determine the safety tolerability and preliminary efficacy of obecabtagene autoleucel in patients with severe refractory systemic lupus erythematosus. ClinicalTrials.gov Identifier: NCT06333483. https:\/\/clinicaltrials.gov\/study\/NCT06333483?term=nct06333483&viewType=Card&rank=1"},{"key":"e_1_3_2_55_2","unstructured":"A single-arm open-label phase I study to determine the safety tolerability and preliminary efficacy of Obe-cel in participants with refractory progressive forms of multiple sclerosis. ClinicalTrials.gov Identifier: NCT07139743. https:\/\/clinicaltrials.gov\/study\/NCT07139743?intr=NCT07139743&viewType=Card&rank=1"},{"key":"e_1_3_2_56_2","unstructured":"Immunotherapy using CAR T-cells to target CD19 for relapsed\/refractory CD19+ primary central nervous system (CNS) lymphoma. ClinicalTrials.gov Identifier: NCT04443829. https:\/\/clinicaltrials.gov\/study\/NCT04443829"},{"key":"e_1_3_2_57_2","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.03: Quick Reference. U.S. Department of Health and Human Services. Published June 14 2010. Accessed April 27 2026. Available from: https:\/\/www.eortc.be\/services\/doc\/ctc\/ctcae_4.03_2010-06-14_quickreference_5x7.pdf"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e19500"},{"key":"e_1_3_2_61_2","unstructured":"US Food and Drug Administration. FDA eliminates Risk Evaluation and Mitigation Strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies. Published 2025. Accessed December 23 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-eliminates-risk-evaluationand-mitigation-strategies-rems-autologous-chimeric-antigen-receptor"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.346"},{"key":"e_1_3_2_63_2","unstructured":"Coding billing guide. Accessed May 18 2026. https:\/\/www.autolusassist.com\/downloads\/product-coding-and-billing-guide.pdf"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19012"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1692287"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01405"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-025-00771-z"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2025.2523551"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261470829","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261470829","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261470829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:23:16Z","timestamp":1786605796000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261470829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":72,"alternative-id":["10.1177\/10600280261470829"],"URL":"https:\/\/doi.org\/10.1177\/10600280261470829","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"10600280261470829"}}